New Book Challenges Conventional Dementia Care, Advocates for Non-Invasive Gamma Stimulation
Mark L. Fox's 'The Memory Room' presents evidence that cognitive decline may be mitigated through 40 Hz gamma stimulation, based on MIT research and a clinical study showing cognitive improvement in all 41 participants.
At a time when more than 55 million people worldwide are living with dementia, a new book is challenging the assumption that little can be done beyond managing symptoms. Mark L. Fox, founder of Resona Health and former aerospace engineer, has released The Memory Room: A New Way to Create Clarity, Calm, and Connection in Assisted Living, which explores the science behind cognitive variability and non-pharmacological interventions that may help individuals experience more moments of clarity and connection.
Drawing on research from MIT's Picower Institute for Learning and Memory and a completed Phase 1 study, Fox argues that the 'good days' observed in memory care are not random but may reflect measurable changes in neural function that can be supported through safe interventions. The book focuses on 40 Hz gamma stimulation, an area of neuroscience that gained attention after MIT studies showed it may influence biological processes related to brain health, including microglial activation and neural network coordination.
Central to the discussion is BlueVibe, a wearable device developed by Resona Health that combines pulsed electromagnetic field (PEMF) technology and pulsed blue light stimulation at 40 Hz. A six-week Phase 1 study involving 41 participants reported that all 41 showed improvement in cognitive function scores, none experienced regression, and no adverse effects were reported. The statistical analysis produced a p-value of less than 0.000001.
Fox emphasizes that neither BlueVibe nor any existing technology should be viewed as a cure for Alzheimer's disease or dementia. 'This is not a book about curing dementia,' Fox explained. 'It's about supporting the brain's remaining capacity. It's about helping residents access more of the abilities they still have. It's about creating more opportunities for connection, communication, and quality of life.'
The book is written for assisted living operators, memory care directors, healthcare administrators, clinicians, caregivers, and families seeking evidence-informed approaches to supporting cognitive function. It discusses non-drug interventions, implementation challenges in senior living, caregiver burnout, and the growing demand for innovative memory care solutions.
Early readers have described the book as scientifically accessible and emotionally compelling, combining neuroscience, real-world caregiver experiences, and practical strategies. The Memory Room is available on Amazon.
The implications of this book are significant for the dementia care industry, which has long relied on pharmacological management. If non-invasive gamma stimulation can consistently produce cognitive improvements, it could reshape standards of care, reduce reliance on drugs with side effects, and improve quality of life for millions. However, Fox cautions that more research is needed, and the book is a call to action for further study and adoption of evidence-based non-pharmacological interventions.